View : 324 Download: 0
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
- Title
- MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
- Authors
- Han E.; Chun H.S.; Lee Y.-H.; Lee J.S.; Lee H.W.; Kim B.K.; Park J.Y.; Kim D.Y.; Lee B.-W.; Kang E.S.; Cha B.-S.; Ahn S.H.; Kim S.U.
- Ewha Authors
- 전호수
- SCOPUS Author ID
- 전호수
- Issue Date
- 2023
- Journal Title
- Journal of Gastroenterology and Hepatology (Australia)
- ISSN
- 8159-9319
- Citation
- Journal of Gastroenterology and Hepatology (Australia) vol. 38, no. 9, pp. 1598 - 1609
- Keywords
- Cardiovascular disease; Liver fibrosis; Metabolic dysfunction-associated fatty liver disease; Non-alcoholic fatty liver disease; Sarcopenia
- Publisher
- John Wiley and Sons Inc
- Indexed
- SCOPUS
- Document Type
- Article
- Abstract
- Background and Aim: Clinical features of non-alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria of metabolic dysfunction-associated fatty liver disease (MAFLD), remain unclear. We investigated the risk of sarcopenia and cardiovascular disease (CVD) in MAFLD and non-metabolic risk (MR) NAFLD. Methods: Subjects were selected from the Korean National Health and Nutrition Examination Surveys 2008–2011. Liver steatosis was assessed using fatty liver index. Significant liver fibrosis was defined using fibrosis-4 index, categorized by age cut-offs. Sarcopenia was defined as the lowest quintile sarcopenia index. Atherosclerotic CVD (ASCVD) risk score > 10% was defined as high probability. Results: A total of 7248 subjects had fatty liver (137 with non-MR NAFLD, 1752 with MAFLD/non-NAFLD, and 5359 with overlapping MAFLD and NAFLD). In non-MR NAFLD group 28 (20.4%) had significant fibrosis. The risk of sarcopenia (adjusted odds ratio [aOR] = 2.71, 95% confidence index [CI] = 1.27–5.78) and high probability of ASCVD (aOR = 2.79, 95% CI = 1.23–6.35) was significantly higher in MAFLD/non-NAFLD group than in non-MR NAFLD group (all P < 0.05). The risk of sarcopenia and high probability of ASCVD was similar between subjects with and without significant fibrosis in non-MR NAFLD group (all P > 0.05). However, the risk was significantly higher in MAFLD group than in non-MR NAFLD group (aOR = 3.38 for sarcopenia and 3.73 for ASCVD; all P < 0.05). Conclusions: The risks of sarcopenia and CVD were significantly higher in MAFLD group but did not differ according to fibrotic burden in non-MR NAFLD group. The MAFLD criteria might be better for identifying high-risk fatty liver disease than the NAFLD criteria. © 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
- DOI
- 10.1111/jgh.16261
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML